Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Peritoneal Neoplasms × talimogene laherparepvec × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 17 Sarcoma 7 Breast Neoplasms 5 Carcinoma, Merkel Cell 4 Triple Negative Breast Neoplasms 3 Neoplasm Metastasis 3 Carcinoma, Squamous Cell 3 Mycosis Fungoides 2 Lymphoma, T-Cell, Cutaneous 2 Carcinoma, Basal Cell 2 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Sezary Syndrome 1 Sarcoma, Kaposi 1 Recurrence 1 Rectal Neoplasms 1 Pleural Effusion, Malignant 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Paget Disease, Extramammary 1 Neurofibromatosis 1 1 Neurofibromatoses 1 Neurofibroma 1 Muir-Torre Syndrome 1 Microcystic adnexal carcinoma 1 Lymphoma, T-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lung Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1

Interventions

Hyperthermic Intraperitoneal Chemotherapy 21 Paclitaxel 20 Cisplatin 17 Cytoreduction Surgical Procedures 16 Oxaliplatin 13 Carboplatin 12 Fluorouracil 9 Bevacizumab 9 Mitomycin 6 Doxorubicin 6 Leucovorin 5 Docetaxel 5 Surgical Procedures, Operative 4 Neoadjuvant Therapy 4 Blood Specimen Collection 4 sodium thiosulfate 3 catumaxomab 3 Gemcitabine 3 Drug Therapy 3 Chemotherapy, Adjuvant 3 130-nm albumin-bound paclitaxel 3 relacorilant 2 pembrolizumab 2 olaparib 2 nintedanib 2 liposomal doxorubicin 2 Taxes 2 Palliative Care 2 Observation 2 Nivolumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03663712 2024-11-20

TEMPO

Duke University

Phase 1 Completed

28 enrolled 10 charts

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡